OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

Original reporting
Published Nov 17, 2026, 5:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 5:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares — source image
Decision brief

The 30-second read

$OMERBearishMed
01

Why it matters

For traders, the key decision inputs are reduced forward visibility (no Q4/2027 sales guidance now) and a concrete timeline slip for OMS527 enrollment, both of which can affect near-term positioning and options pricing ahead of future updates.

02

Market read

OMER faces heightened uncertainty around 2027 revenue timing due to guidance omission and a CRO-driven clinical trial enrollment delay, despite retail sentiment improving.

03

What to watch

The article does not quantify how much the guidance delay changes consensus estimates, and it frames the OMS527 delay as CRO logistics rather than scientific failure.

Relevance 7/10Novelty 6/10Timing: today, as investors digest guidance omission and the OMS527 trial delay

Background

The piece discusses Omeros management commentary on withholding sales guidance and a separate delay to the OMS527 inpatient clinical trial start, alongside retail sentiment and mention of the Novo Nordisk collaboration.

Company-level read

Ticker impact

$OMERBearishHigh confidence
Context

Omeros said it will not provide Q4 or 2027 sales guidance yet and delayed the OMS527 cocaine-use-disorder trial enrollment to early 2027.

Expected impact

Shares likely face continued downside or volatility as investors reprice delayed visibility into 2027 sales and trial enrollment.

Evidence & confidence

The article contains two company-specific, time-sensitive updates: no near-term sales guidance and a CRO-driven delay pushing inpatient trial enrollment into early 2027.

Market effects

Biotech sentiment may soften for CNS/addiction programs when trial enrollment timelines slip, even without new efficacy data.

Limited, mostly US small/mid-cap biotech sentiment spillover.

Low, as the updates are company-specific and not a cross-market macro catalyst.

Counterpoint

The company still expects 2027 trial data and highlights ongoing reimbursement add-on economics for Yartemlea plus a Novo Nordisk partnership with large milestone eligibility.

Key entities

  • Omeros

    Subject of the article, with guidance withheld and OMS527 trial enrollment delayed to early 2027.

  • Novo Nordisk

    Mentioned as a partner in a collaboration with milestone and royalty eligibility.

  • OMS527

    Experimental drug in cocaine use disorder, with inpatient trial enrollment delayed to early 2027.

  • Yartemlea

    New technology add-on payment effective October 1, cited as supporting additional Medicare reimbursement for eligible inpatient cases.

Related articles

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q